AFT Pharmaceuticals director increases stake in company

David Flacks, a director and chair of AFT Pharmaceuticals Limited, disclosed an acquisition of fully-paid ordinary shares in the company. The transaction, reported on September 1, 2025, involved two on-market purchases made on August 28, 2025, and August 29, 2025. These transactions resulted in an increase of 17,722 shares in Flacks' holdings.

The total consideration for these acquisitions amounted to NZD 48,206, with an average purchase price of NZD 2.72 per share. Following these transactions, the number of shares held by David Flacks, jointly with Adina Rita Betty Halpern as trustees of Waitemata Family Trust, increased from 178,764 to 196,486. These shares are held as a joint registered holder and beneficial owner. The disclosure confirms that the acquisition did not occur during a closed period, and no prior written clearance was required.

This announcement reflects a notable change in the shareholding of a key executive at AFT Pharmaceuticals, indicating continued investment by its leadership.